Skip to main content

Advertisement

Cancer proteomics

Conclusion

The future of cancer diagnostics will be based on a panel of proteomic biomarkers. They could be used to detect cancer at an early stage, to predict and to direct therapies. Enzymes and related proteins are important biological molecules, which could serve as cancer biomarkers. These biomarkers could be intact or fragments of proteins. The challenge is to be able to find and validate these potential biomarkers as clinical diagnostics. With the advances in proteomic technologies, we are closer than ever to find these “new” enzyme molecules or fragments. The translation of newly discovered biomarkers could provide an opportunity to revolutionize the era of personalized medicine.

References

  1. 1.

    Anderson, N. L. and Anderson, N. G. (2002) The human plasma proteome: history, character, and diagnostic prospects.Mol. Cell. Proteomics 1, 845–867.

  2. 2.

    McDonald, W. H. and Yates, J. R., 3rd. (2002) Shotgun proteomics and biomarker discovery.Dis. Markers 18, 99–105.

  3. 3.

    Colantonio, D. A. and Chan, D. W. (2005). The clinical application of proteomics.Clin. Chimica. Acta 357, 151–158.

  4. 4.

    Tirumalai, R. S., Chan, K. C., Prieto, D. A., Issaq, H. J., Conrads, T. P., and Veenstra, T. D. (2003) Characterization of the low molecular weight human serum proteome.Mol. Cell. Proteomics 2, 1096–1103.

  5. 5.

    Rodland, K. D. (2004) Proteomics and cancer diagnosis: the potential of mass spectrometry.Clin. Biochem. 37, 579–583.

  6. 6.

    Zhang, Z. and Chan, D. W. (2005) Cancer proteomics: in pursuit of “true” biomarker discovery.Cancer Epidemiol. Biomarkers Prev. 14, 2283–2286.

  7. 7.

    Rifai, N., Gillette, M. A., and Carr, S. A. (2006) Protein biomarker discovery and validation: the long and uncertain path to clinical utility.Nat. Biotechnol. 24, 971–983.

  8. 8.

    Mikolajczyk, S. D., Millar, L. S., Wang, T. J., et al. (2000) A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue.Cancer Res. 60, 756–759.

  9. 9.

    Chen Z, Chen H, Stamey TA. (1997) Prostate specific antigen in benign prostatic hyperplasia: purification and characterization.J. Urol. 157, 2166–2170.

  10. 10.

    Mikolajczyk, S. D., Song, Y., Wong, J. R., Matson, R. S., and Rittenhouse, H. G. (2004) Are multiple markers the future of prostate cancer diagnostics?Clin. Biochem. 37, 519–528.

  11. 11.

    Sokoll, L. J., Chan, D. W., Mikolajczyk, S. D., et al. (2003) Proenzyme psa for the early detection of prostate cancer in the 2.5–4.0 ng/ml total psa range: preliminary analysis.Urology 61, 274–276.

  12. 12.

    Zhang, Z, Bast, R. C., Jr, Yu, Y., et al. (2004) Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer.Cancer Res. 64, 5882–5890.

  13. 13.

    Song, J., Patel, M., Rosenzweig, C. N., et al. (2006) Quantification of fragments of human serum inter-alpha-trypsin inhibitor heavy chain 4 by a surface-enhanced laser desorption/ionization-based immunoassay.Clin. Chem. 52, 1045–1053.

Download references

Author information

Correspondence to Daniel W. Chan.

Rights and permissions

Reprints and Permissions

About this article